Abstract CT250: A phase 1b / 2 study of JK06, a 5T4-targeted antibody drug conjugate, in patients with unresectable locally advanced or metastatic cancer
Omar Saavedra(Hospital Quirónsalud Barcelona), Nuria Kotecki(Centre Oscar Lambret), Jijun Dong(Integrated BioTherapeutics (United States)), B. Dekeyser(Antwerp University Hospital), Vladimir Galvao(Hebron University), Naimish Pandya(Integrated BioTherapeutics (United States)), Judit W. Johnson(Integrated BioTherapeutics (United States)), Jonathan P. McNally(Integrated BioTherapeutics (United States)), Lionel D’Hondt(CHU Dinant Godinne UCL Namur), Shalabh Singhal(Integrated BioTherapeutics (United States)), Brant Delafontaine(Ghent University Hospital), A. Drumheller(Integrated BioTherapeutics (United States)), Jennifer Lindelien(Integrated BioTherapeutics (United States)), Sylvie Rottey(Ghent University Hospital), Samuel P. Murphy(Integrated BioTherapeutics (United States)), Valentina Gambardella(INCLIVA Health Research Institute), Hans Prenen(Antwerp University Hospital), Maria deMiguel(Center for Biomedical Research of La Rioja), V. Boni(Hospital Universitario Quirónsalud Madrid), Emiliano Calvo, Fabricio Racca(Instituto Oncológico Dr. Rosell)
Cited by 0
Related Papers
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC
|JAMA Oncology|2018|315
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled</scp> Trial
|Arthritis & Rheumatology|2022|261
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial
|Neuro-Oncology|2022|247
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
|Annals of the Rheumatic Diseases|2022|212
Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors
|Clinical Cancer Research|2021|111